Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.59 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.55 |
| ▸ | CECR2 | Q9BXF3 | 4/20 | 0.49 |
| ▸ | TAF1 | P21675 | 3/20 | 0.49 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729754 | 0.85 | BRD4 (0.51) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL19871750 | 0.81 | BRD4 (0.55) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL22516602 | 0.80 | BRD4 (0.58) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL22600098 | 0.80 | BRD4 (0.58) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL15069208 | 0.80 | BRD4 (0.58) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL24556455 | 0.79 | BRD4 (0.56) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL21445298 | 0.77 | BRD4 (0.55) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL20385458 | 0.77 | BRD9 (0.48) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL24866050 | 0.77 | BRD4 (0.76) | BRD4BRD9CECR2TAF1 | |
| SCHEMBL31590544 | 0.77 | BRD4 (0.65) | BRD4BRD9CECR2TAF1BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2020219168-A1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE, LLC (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020055976-A1 | TERT-BUTYL (S)-2-(4-(PHENYL)-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AND RELATED COMPOUNDS AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | GENENTECH, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020020288-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2020-01-30 | — | — | WO | disclosed |
| WO-2020007322-A1 | COMPOUND TARGETED TO DEGRADE BET PROTEIN AND APPLICATION THEREOF | 清华大学 | 2020-01-09 | — | — | WO | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | BRD4 541/4885BRD9 1004/4885CECR2 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.